• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Spectral Medical Inc

Spectral Medical wins FDA nod for Spectral Apheresis Machine

December 28, 2017 By Fink Densford

Spectral Medical (TSX:EDT) said this month it won FDA 510(k) clearance for its Spectral Apheresis Machine designed for use in continuous renal replacement therapy and therapeutic plasma exchange. The SAM device was developed to support commercialization of the company’s Toraymyxin, or PMX therapy, to enable intensive care units to be able to safely and efficiently deliver […]

Filed Under: 510(k), Drug Pumps, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Spectral Medical Inc

Spectral Medical’s Toraymyxin fails pivotal trial

October 3, 2016 By Brad Perriello

A clinical trial of the Toraymyxin anti-sepsis device made by Spectral Medical (TSX:EDT) failed to meet its primary endpoint, sending share prices on a -81.1% plunge today. Toronto-based Spectral developed a stand-alone pump, the Toraymyxin device, designed for use with an assay to identify endotoxin levels. The system aims to use a 2-column hemoperfusion to remove septic […]

Filed Under: Hospital Care, Wall Street Beat Tagged With: Spectral Medical Inc

Spectral Medical takes a mystery dive, recovers

August 19, 2016 By Brad Perriello

Shares in Spectral Medical (TSX:EDT) took a mystery dive yesterday, plunging -33.9% before recovering today and leaving even the sepsis treatment maker shaking its head. Toronto-based Spectral, which earlier this week said it plans to file its final pre-market approval module with the FDA for its Toraymyxin device by the end of the year, said today that “its management and […]

Filed Under: Hospital Care, Wall Street Beat Tagged With: Spectral Medical Inc

Spectral Medical eyes final PMA bid by year-end for Toraymyxin anti-sepsis device

August 18, 2016 By Brad Perriello

Spectral Medical (TSX:EDT) said today that it plans to file its final pre-market approval module with the FDA for its sepsis treatment by the end of the year, after the impending release of primary endpoint data from a clinical trial. The Toronto-based company developed a stand-alone pump, the Toraymyxin device, designed for use with an assay […]

Filed Under: Food & Drug Administration (FDA), Hospital Care, Regulatory/Compliance Tagged With: Sepsis, Spectral Medical Inc

Leading the battle against sepsis: A MassDevice podcast with Spectral Medical CEO Paul Walker

June 30, 2016 By Fink Densford

Spectral Medical CEO Dr. Paul Walker has been focused on finding a solution to identify and treat sepsis, and specifically endotoxins that are known to trigger it, for over 20 years. Sepsis affects approximately 1 million patients in the U.S. each year, and even more worldwide – and treating the deadly condition has proved to […]

Filed Under: Blood Management, Business/Financial News Tagged With: Spectral Medical Inc

Spectral Medical wins compassionate use exemption for Toramyxicin

June 27, 2016 By Fink Densford

Spectral Medical said today it won compassionate use expanded access from the FDA for its Toraymyxin blood treatment device designed for removing endotoxins from patient’s blood. The Toraymyxin is an investigational therapeutic hemoperfusion device designed to treat patients in septic shock with elevated levels of endotoxins. “As we move to complete our PMA submission for Toraymyxin with […]

Filed Under: Blood Management, Regulatory/Compliance Tagged With: Spectral Medical Inc

Spectral Medical touts PMA acceptance for sepsis treatment

June 16, 2016 By Fink Densford

Spectral Medical today announced the FDA has reviewed and accepted 1 of 2 pre-clinical modules in its premarket approval application for its Toraymyxin device designed to remove endotoxins from the bloodstream. The Toraymyxin is an investigational therapeutic hemoperfusion device designed to treat patients in septic shock with elevated levels of endotoxins. The Canadian company touted study […]

Filed Under: Blood Management, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Spectral Medical Inc

Spectral Medical closes over-allotment, brings in $10.5m in round

February 24, 2016 By Fink Densford

Spectral Medical said today it closed an over-allotment on its most recent round of financing, selling an additional 806,804 shares at 70¢ per share to lift the round to $10.5 million Toronto-based Spectral makes a system designed to diagnose and remove endotoxin from the bloodstream. The offering was underwritten by a syndicate led by Cormark […]

Filed Under: Blood Management, Business/Financial News Tagged With: Spectral Medical Inc

Spectral Medical looks to raise $10m

January 29, 2016 By Brad Perriello

Spectral Medical said it inked a deal for a $10 million stock sale it plans to use to fund a clinical trial. Toronto-based Spectral makes a system designed to diagnose and remove endotoxin from the bloodstream. The offering involves the purchase of 14.3 million shares at 70¢ apiece by a consortium of underwriters, who plan […]

Filed Under: Funding Roundup, Hospital Care Tagged With: Spectral Medical Inc

Spectral Medical inks distribution deal with Fresenius

November 10, 2015 By Fink Densford

Septic shock treatment developer Spectral Medical said today it inked a deal with Fresenius Medical Care to distribute its Endotoxin activity assay devices. Fresenius will be the non-exclusive distributor of the device in Germany, Denmark, Sweden, Finland, Norway, Poland, Hungary and the Czech Republic, the company said. “We are very pleased to have entered into […]

Filed Under: Blood Management, Business/Financial News, Distribution Tagged With: Fresenius, Spectral Medical Inc

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy